Shares of Manchester-based molecular diagnostics company Genedrive rose about 7% on Monday after it announced it has been successful with its tender into Public Health England (PHE) under Lot 1 of the National Microbiology Framework (Diagnostic Goods and Services).
“The PHE tender was opened in November 2020 and sought to appoint suppliers to a multi-lot national microbiology framework agreement relating to the supply of Diagnostics Goods and Services and covering Clinical Laboratory Diagnostic Testing Services,” said Genedrive.
“The award of a framework contract is not exclusive to the company, nor a guarantee of orders, however it does allow participating authorities to issue call-off orders for products in the future.
“All of genedrive’s currently available and CE marked products fall within the framework agreement: Genedrive 96 SARS-CoV-2 Kit, Genedrive HCV ID Kit, Genedrive MT-RNR1 ID Kit.”
Genedrive CEO David Budd said: “We are very pleased to have received notice of this contract award decision and look forward to the opportunity to engage with PHE and relevant authorities on future potential contracts.
“This is an early notification of the decision and we will update shareholders when we have more information on what this contract may mean for orders and revenues”.